Progesterone Receptor Status May be the Most Important Prognostic Factor for Meningiomas

Basit Öğe Kaydı
dc.contributor.authorCetin, Abdurrahman
dc.contributor.authorLacin, Sahin
dc.contributor.authorSogutcu, Nilgun
dc.date.accessioned2024-04-24T17:24:48Z
dc.date.available2024-04-24T17:24:48Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe aim of this study examined the relationships between progesterone receptor (PR) and estrogen receptor (ER) status in meningiomas and tumor grade, proliferative index (Ki67), and prognosis. Immunohistochemistry with monoclonal rabbit antibodies was performed on 4 mm paraffin sections of all tumors that were confirmed as meningiomas. Samples were assessed for tumor grade, PR and ER expression, and Ki67 status. Correlations among these parameters and their prognostic values were investigated. Overall survival (OS) was 91.4 months, and there was a significant difference in OS between genders. OS for females and males was 100.2 and 45.7 months, respectively (p= 0.02). When patients were divided into two groups by age, there was a significant difference in OS between those aged 50 years and younger and those older than 50 years, 113.2 and 65.1 months, respectively (p= 0.001). There was also a significant difference in OS based on PR status. OS among PR-negative patients was 43.8 months, whereas it was 93.7 months in weakly positive patients, and 95.2 months in strongly positive patients (p= 0.035). Overall, 10 (13.5%) patients had ER expression detectable by the monoclonal antibody technique used. All ER-positive tumor samples were from female patients; all tumors from males were negative for ER staining. Female predominance of meningiomas as the most common primary intracranial neoplasm strongly suggests that sex hormones may affect meningioma growth. This study found that PR status was a prognostic factor in our meningioma series, as were gender and age.en_US
dc.identifier.doi10.4999/uhod.193115
dc.identifier.endpage45en_US
dc.identifier.issn1306-133X
dc.identifier.issue1en_US
dc.identifier.startpage38en_US
dc.identifier.urihttps://doi.org/10.4999/uhod.193115
dc.identifier.urihttps://hdl.handle.net/11468/19838
dc.identifier.volume29en_US
dc.identifier.wosWOS:000465618700006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherAkad Doktorlar Yayinevien_US
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMeningiomaen_US
dc.subjectEstrogen Receptoren_US
dc.subjectProgesterone Receptoren_US
dc.subjectGradeen_US
dc.subjectNeoplasmen_US
dc.titleProgesterone Receptor Status May be the Most Important Prognostic Factor for Meningiomasen_US
dc.titleProgesterone Receptor Status May be the Most Important Prognostic Factor for Meningiomas
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu